Psilocybin Could Help Treat Nearly 264 Million with Depression

Small Cap Biotech Stocks

Mental health is on the decline all over the world.  In fact, as you read this, nearly 264 million people are struggling with depression, for example.  While some of us are better at hiding our depression than others, it can be a real struggle, especially with the potential anxiety, irritability, and hopelessness.  Many even “put on a face” so others aren’t aware of how they really feel.  It’s not fun.  It’s not easy.  To help alleviate the symptoms of depression, many turn to anti-depressants such as SSRIs (selective serotonin reuptake inhibitors). Problem is — SSRIs aren’t always useful, focusing more on symptom suppression than root cause.

Fortunately, companies are finding that psychedelics, like psilocybin may be useful, including MYND Life Sciences Inc. (CSE:MYND), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Mind Medicine Inc. (NASDAQ:MNMD)(NEO:MMED), Compass Pathways (NASDAQ:CMPS), KetamineOne Capital Limited (NEO:MEDI)(OTC:KONEF).

In addition, the US FDA is backing research into psilocybin.  In 2018, for example, the agency recognized psilocybin as “breakthrough therapy” for depression. Two, clinical studies from the likes of Johns Hopkins, and New York University are already showing positive results.  A study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.  Plus, The Beckley Foundation said, “Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.”